Breaking Barriers: OTC Birth Control Pill Hits U.S. Shelves

Opill: A Landmark in Contraceptive Accessibility

Opill is an oral contraceptive manufactured by Perrigo and represents the first product of its kind legally available on the U.S. market without a prescriptions. The U.S. Food and Drug Administration approved this drug in July 2023. Its decision

 was widely anticipated and received with a warm welcome from all reproductive health advocates. 

Unlike combined contraceptive medications, which contain two types of hormones, Opill supplements only progestin. However, when used continuously and correctly, it maintains 98% efficacy. As Dr. Melissa Kottke, an associate professor at Emory University School of Medicine, noted, “Progestin-only pills have been a trusted contraceptive option for decades; however, needless barriers to birth control pills remain when the contraception needs a prescription.”

Opill’s pricing aligns with the expectations of many potential users, with a suggested retail price of $19.99 for a one-month supply, catering to the affordability thresholds expressed by survey respondents.

Empowering Choice and Reducing Unintended Pregnancies

With almost half of all pregnancies in the U.S. being unplanned, as reported by the FDA, the introduction of OTC birth control pills is a critical milestone in changing this alarming statistic. Opill is available not only at pharmacies like Walgreens and CVS but also through nationwide retailers and online providers, ensuring convenient and discreet access to contraception.

Opill exemplifies success in the ongoing fight for healthcare equality and individual freedom by reducing barriers to access and empowering individuals with the information they need to make informed choices about their reproductive health.

With the advent of over-the-counter birth control pills, the landscape of reproductive health is evolving rapidly. It’s important to prioritize the health of your female empliyees. Contact us today to explore customized insurance plans that put their reproductive health needs first.